Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3200882 + Pembrolizumab in Advanced Cancer
NCT04158700Phase 2Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2019
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of ly3200882 in urothelial carcinoma (UC), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), sponsored by Eli Lilly and Company. Planned start Dec 2019; status: withdrawn.
02
Drugs
ly3200882
03
Conditions
urothelial carcinoma (UC)non-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04158700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04158700.